Success Metrics

Active Trials
3(60%)

Phase Distribution

Ph not_applicable
1
20%
Ph phase_3
3
60%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 3Large-scale testing
3(75.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(5)

Detailed Status

Not yet recruiting2
Recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 33 (75.0%)
N/A1 (25.0%)

Trials by Status

not_yet_recruiting240%
recruiting240%
active_not_recruiting120%

Recent Activity

3 active trials
Showing 5 of 5
not_yet_recruitingphase_3

Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC

NCT07554846
not_yet_recruitingphase_3

De-Escalation Surgery After Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT07320690
recruiting

Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma

NCT05595408
active_not_recruitingnot_applicable

NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC

NCT06762158
recruitingphase_3

Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma

NCT05877872

Clinical Trials (5)

Showing 5 of 5 trials
NCT07554846Phase 3

Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC

Not Yet Recruiting
NCT07320690Phase 3

De-Escalation Surgery After Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

Not Yet Recruiting
NCT05595408

Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma

Recruiting
NCT06762158Not Applicable

NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC

Active Not Recruiting
NCT05877872Phase 3

Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma

Recruiting

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5